New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Cidara Therapeutics, Inc.

Contributing Author

Recent Articles by Cidara Therapeutics, Inc.

Oct-02	Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic CDTX GlobeNewswire
Sep-25	Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations CDTX GlobeNewswire
Sep-24	Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza CDTX GlobeNewswire
Sep-17	Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting CDTX GlobeNewswire
Sep-04	Cidara Therapeutics to Participate in September Investor Conferences CDTX GlobeNewswire
Sep-03	Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting CDTX GlobeNewswire
Aug-07	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CDTX GlobeNewswire
Jul-24	Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 CDTX GlobeNewswire
Jul-01	Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) CDTX GlobeNewswire
Jun-30	Cidara Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes CDTX GlobeNewswire
Jun-26	Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares CDTX GlobeNewswire
Jun-24	Cidara Announces Pricing of Upsized Public Offering of Common Stock CDTX GlobeNewswire
Jun-23	Cidara Announces Proposed Public Offering of Common Stock CDTX GlobeNewswire
Jun-23	Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza CDTX GlobeNewswire
May-15	Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 CDTX GlobeNewswire
May-13	Cidara Therapeutics to Participate in Two Upcoming Investor Conferences CDTX GlobeNewswire
May-08	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results CDTX GlobeNewswire
May-01	Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development CDTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.